Abstract: Chronic pruritus, a common symptom of dermatologic diseases, impairs quality of life. No review exists that evaluates the efficacy of emerging therapies based on a single standardized scale. We assessed efficacy and adverse effects of novel treatments available for pruritus in patients diagnosed with common pruritic diseases using the proportions of patients experiencing a ≥4-point reduction as a standardized efficacy measure between studies. We searched PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials for phase II or III trials reporting change in numerical rating scale following interventions for pruritus from 2015 to 2023. The strongest improvements in pruritus were seen from ustekinumab (RR 4.30 [2.88; 6.41]) and ixekizumab (RR 4.42 [3.32; 5.88]) for psoriasis and upadacitinib (RR 5.54 [95% CI: 4.53–6.78]), abrocitinib (RR 3.76 [95% CI: 2.97–4.76]), and baricitinib (RR 3.63 [95% CI: 2.36–5.58]) for atopic dermatitis. Nemolizumab (RR 3.06 [95% CI: 1.63–5.74]) and dupilumab (RR 2.11 [95% CI: 1.30–3.41]) were most effective for prurigo nodularis, though fewer studies were available for comparison. Adverse effects were mild and similar between agents; discontinuation rates were low. This review evaluates efficacy of emerging pruritus treatments based on a single standardized measurement, highlighting the role of novel agents in the treatment of chronic pruritus.
Get full access to this article
View all access options for this article.
References
1.
ShiveM, LinosE, BergerT, et al.Itch as a patient-reported symptom in ambulatory care visits in the United States. J Am Acad Dermatol. 2013; 69(4):550–556; doi: 10.1016/j.jaad.2013.05.029
2.
RohYS, ChoiJ, SutariaN, et al.Itch: Epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022; 86(1):1–14; doi: 10.1016/j.jaad.2021.07.076
3.
YosipovitchG, ReaneyM, MasteyV, et al.Peak pruritus numerical rating scale: Psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019; 181(4):761–769; doi: 10.1111/bjd.17744
4.
KimballAB, NaegeliAN, Edson‐HerediaE, et al.Psychometric properties of the Itch Numeric Rating Scale in patients with moderate‐to‐severe plaque psoriasis. Br J Dermatol. 2016; 175(1):157–162.
5.
SterneJAC, SavovićJ, PageMJ, et al.RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:14898; doi: 10.1136/bmj.l4898
6.
BalduzziS, RückerG, NikolakopoulouA, et al.netmeta: An R Package for network meta-analysis using frequentist methods. J Stat Soft. 2023; 106(2):1–40; doi: 10.18637/jss.v106.i02
7.
SterneJAC, EggerM. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol. 2001; 54(10):1046–1055.
8.
BlauveltA, TeixeiraHD, SimpsonEL, et al.Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2021; 157(9):1047–1055; doi: 10.1001/jamadermatol.2021.3023
9.
ReichK, ThyssenJP, BlauveltA, et al.Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial. Lancet. 2022; 400(10348):273–282; doi: 10.1016/S0140-6736(22)01199-0
10.
SilverbergJI, SimpsonEL, ThyssenJP, et al.Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020; 156(8):863–873; doi: 10.1001/jamadermatol.2020.1406
11.
LebwohlMG, GoldLS, StroberB, et al.Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021; 385(24):2219–2229; doi: 10.1056/NEJMoa2103629
12.
SimpsonEL, SinclairR, FormanS, et al.Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020; 396(10246):255–266; doi: 10.1016/S0140-6736(20)30732-7
13.
Guttman-YasskyE, TeixeiraHD, SimpsonEL, et al.Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure up 1 and Measure up 2): Results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021; 397(10290):2151–2168; doi: 10.1016/S0140-6736(21)00588-2
14.
KimBS, HowellMD, SunK, et al.; INCB 18424-206 Study Investigators. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020; 145(2):572–582; doi: 10.1016/j.jaci.2019.08.042
15.
StänderS, YosipovitchG, LegatFJ, et al.Trial of nemolizumab in moderate-to-severe Prurigo Nodularis. N Engl J Med. 2020; 382(8):706–716; doi: 10.1056/NEJMoa1908316
16.
GoldLS, PappK, PariserD, et al.Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2022; 86(1):77–85; doi: 10.1016/j.jaad.2021.07.040
17.
Guttman-YasskyE, BlauveltA, EichenfieldLF, et al.Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial. JAMA Dermatol. 2020; 156(4):411–420; doi: 10.1001/jamadermatol.2020.0079
18.
ZhaoY, WuL, LuQ, et al.The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled study. Br J Dermatol. 2022; 186(4):633–641; doi: 10.1111/bjd.20690
19.
LebwohlMG, KircikLH, MooreAY, et al.Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: The DERMIS-1 and DERMIS-2 randomized clinical trials. JAMA., 2022; 328(11):1073–1084; doi: 10.1001/jama.2022.15632
20.
ZhaoY, ZhangL, DingY, et al.Efficacy and safety of SHR0302, a highly selective janus Kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: A Phase II randomized clinical trial. Am J Clin Dermatol. 2021; 22(6):877–889; doi: 10.1007/s40257-021-00627-2
21.
FujitaK, YagiM, MoriwakiS, et al.A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis. J Dermatol. 2021; 48(11):1640–1651; doi: 10.1111/1346-8138.16120
22.
Van VoorheesAS, GoldLS, LebwohlM, et al.Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020; 83(1):96–103; doi: 10.1016/j.jaad.2020.01.072
23.
YosipovitchG, MollanazarN, StänderS, et al.Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023; 29(5):1180–1190; doi: 10.1038/s41591-023-02320-9
24.
PariserDM, BagelJ, LebwohlM, et al.Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2020; 82(6):1314–1320; doi: 10.1016/j.jaad.2020.01.056
25.
NakagawaH, NemotoO, IgarashiA, et al.Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018; 178(2):424–432; doi: 10.1111/bjd.16014
26.
PeppersJ, PallerAS, Maeda-ChubachiT, et al.A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019; 80(1):89–98.e3; doi: 10.1016/j.jaad.2018.06.047
27.
PallerAS, FlohrC, CorkM, et al.Efficacy and safety of Tralokinumab in adolescents with moderate to severe atopic dermatitis: The phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023; 159(6):596–605; doi: 10.1001/jamadermatol.2023.0627
28.
SofenH, BissonnetteR, YosipovitchG, et al.Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: A randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine., 2023; 57:101826; doi: 10.1016/j.eclinm.2023.101826
29.
ReichK, PinterA, LacourJP, et al.; IXORA-S investigators. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017; 177(4):1014–1023; doi: 10.1111/bjd.15666
30.
UmezawaY, SakuraiS, HoshiiN, et al.; PS0017 Study Group. Certolizumab pegol for the treatment of moderate to severe plaque Psoriasis: 16-Week results from a phase 2/3 Japanese study. Dermatol Ther (Heidelb)., 2021; 11(2):513–528; doi: 10.1007/s13555-021-00494-z
31.
MurataY, SongM, KikuchiH, et al.Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol. 2015; 42(2):129–139; doi: 10.1111/1346-8138.12726
32.
RyanC, MenterA, GuentherL, et al.; IXORA-Q Study Group. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol. 2018; 179(4):844–852; doi: 10.1111/bjd.16736
33.
LandisMN, SmithSR, BersteinG, et al.Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: A phase IIb, randomised, double-blind, vehicle-controlled, parallel-group study. Br J Dermatol. 2023; 189(1):33–41; doi: 10.1093/bjd/ljad098 ((Landis M.N.) Department of Medicine (Dermatology), University of Louisville School of Medicine, Louisville, KY, United States (Landis M.N.) Dermatology and Skin Cancer Center of South Indiana, Corydon, IN, United States (Smith S.R.) California Dermatology).
34.
MaL, ZhangL, KobayashiM, et al.Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild-to-moderate atopic dermatitis. Journal of Dermatology. 2023; doi: 10.1111/1346-8138.16792 ((Ma L.) Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China (Zhang L.) Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China (Kobayashi M.) Sugamo Kobayashi Derma Clini).
35.
NumerickayaKP, RissME. Prospects of using the genetically engineered preparation dupilumab for the treatment of atopic dermatitis in the adult population. Journal of Pakistan Association of Dermatologists., 2022; 32(2):327–333.
36.
WeisshaarE, SzepietowskiJC, BernhardJD, et al.Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase. J Eur Acad Dermatol Venereol. 2022; 36(3):453–461; doi: 10.1111/jdv.17816
37.
PallerAS, SeygerMMB, Alejandro MagariñosG, et al.; IXORA-PEDS study group. Efficacy and safety of ixekizumab in a phase III, randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis (IXORA‐PEDS). Br J Dermatol. 2020; 183(2):231–241; doi: 10.1111/bjd.19147
38.
SimpsonEL, LacourJ‐P, SpelmanL, et al.Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials. Br J Dermatol. 2020; 183(2):242–255; doi: 10.1111/bjd.18898
39.
SimpsonEL, BieberT, Guttman-YasskyE, et al.; SOLO 1 and SOLO 2 Investigators. Two Phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016; 375(24):2335–2348; doi: 10.1056/NEJMoa1610020
40.
StänderS, KwonP, HirmanJ, et al.; TCP-102 Study Group. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. J Am Acad Dermatol. 2019; 80(5):1395–1402; doi: 10.1016/j.jaad.2019.01.052
41.
SimpsonEL, FormanS, SilverbergJI, et al.Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021; 85(1):62–70; doi: 10.1016/j.jaad.2021.02.028
42.
PappK, SzepietowskiJC, KircikL, et al.Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021; 85(4):863–872; doi: 10.1016/j.jaad.2021.04.085
43.
LebwohlMG, PappKA, Stein GoldL, et al.; ARQ-151 201 Study Investigators. Trial of roflumilast cream for chronic plaque psoriasis. N Engl J Med. 2020; 383(3):229–239; doi: 10.1056/NEJMoa2000073
44.
GriffithsCEM, ReichK, LebwohlM, et al.; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541–551; doi: 10.1016/S0140-6736(15)60125-8
45.
WollenbergA, BlauveltA, Guttman-YasskyE, et al.; ECZTRA 1 and ECZTRA 2 study investigators. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)*. Br J Dermatol. 2021; 184(3):437–449; doi: 10.1111/bjd.19574
46.
Guttman-YasskyE, PavelAB, ZhouL, et al.GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019; 144(2):482–493.e7; doi: 10.1016/j.jaci.2018.11.053
47.
KircikLH, Alonso-LlamazaresJ, BhatiaN, et al.Once-daily roflumilast foam 0.3% for scalp and body psoriasis: A randomized, double-blind, vehicle-controlled phase IIb study. Br J Dermatol. 2023; 189(4):392–399; doi: 10.1093/bjd/ljad182
48.
KwatraSG, YosipovitchG, LegatFJ, et al.; OLYMPIA 2 Investigators. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023; 389(17):1579–1589; doi: 10.1056/NEJMoa2301333
49.
SilverbergJI, LioPA, SimpsonEL, et al.Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: A randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial. EClinicalMedicine., 2023; 60:102002; doi: 10.1016/j.eclinm.2023.102002
50.
QureshiAA, AbateLE, YosipovitchG, et al.A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019; 80(3):756–764; doi: 10.1016/j.jaad.2018.09.020
51.
SimonsenE, KomendaP, LernerB, et al.Treatment of uremic pruritus: A systematic review. Am J Kidney Dis. 2017; 70(5):638–655; doi: 10.1053/j.ajkd.2017.05.018
52.
Rodriguez-Le RoyY, FicheuxA-S, MiseryL, et al.Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. Front Med (Lausanne)., 2022; 9:1079323.
53.
ThérénéC, BrenautE, BarnetcheT, et al.Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis. J Invest Dermatol. 2018; 138(1):38–45; doi: 10.1016/j.jid.2017.05.039
54.
von HippelPT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med Res Methodol. 2015; 15(1):35; doi: 10.1186/s12874-015-0024-z
55.
KabashimaK, MatsumuraT, KomazakiH, et al.; Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020; 383(2):141–150; doi: 10.1056/NEJMoa1917006
56.
ArmstrongAW, PuigL, JoshiA, et al.Comparison of biologics and oral treatments for plaque psoriasis: A meta-analysis. JAMA Dermatol. 2020; 156(3):258–269; doi: 10.1001/jamadermatol.2019.4029
57.
Husein-ElAhmedH, SteinhoffM. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatolog Treat. 2022; 33(3):1547–1553; doi: 10.1080/09546634.2020.1853024
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
